Black box warnings could limit the sales of their newly approved therapeutics.
At a conference largely focused on big biopharma a few biotech catalysts stand out.
The first of 2021’s eight remaining oncology meetings kicks off next week. Here’s what to look out for.
Astrazeneca/Daiichi’s Enhertu and Roche’s Polivy both score in pivotal trials that could see them threaten early-line incumbents.
The anti-Tigit MAb domvanalimab will generate key clinical results any day; will they be good enough for Gilead to opt in?